Stay updated with breaking news from Access Pathway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TOKYO, May 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid
STOCKHOLM, May 22, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...
All-cash transaction, with full $87.5 million to be paid at closing Proceeds expected to extend cash runway into Q4 2024 ... | May 22, 2023
Treatment involves early Alzheimer’s disease and will be potentially used across Great Britain - News - PharmaTimes
/PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that they have submitted a Marketing Authorisation Application...